BTG unit pleads guilty in U.S. to misbranding, to pay $36 million

(Reuters) - A U.S. unit of British drug company BTG Plc pleaded guilty on Monday to improperly marketing its embolic device LC Bead, and will pay about $36 million to resolve its criminal and civil liability, the U.S. Department of Justice said.